Market Overview

Morgan Stanley Sees EPS Below Consensus, Robust Pipeline For Alkermes plc

Share:
Related ALKS
15 Stocks Which Rallied Four Days, Then Sold Off Yesterday
11 Biopharma CEOs To Follow On Twitter
Virgin Extends Drop As Alaska Air Merger Review Grows Longer (Investor's Business Daily)

In a report published Thursday, Morgan Stanley analyst David Risinger reiterated an Equal-Weight rating on Alkermes plc (NASDAQ: ALKS).

In the report, Morgan Stanley noted, “We reduced 2014E EPS from $0.52 to $0.30, near the upper end of management guidance of $0.19–0.32.The main driver was increase in 2014E R&D expenses from $239M to $275M (guidance $260–280M). Boosting out-year R&D spending yielded EPS far below consensus.We cutEPS as follows: '15E from $0.42 to $0.08 in '15E (vs.cons' $0.59), '16E from $0.80 to $0.35 (vs.cons' $1.24), '17E from $1.30 to $0.94 (vs.cons' $1.95),and '18E from $1.76 to $1.41 (vs.cons' $2.79).”

Alkermes plc closed on Wednesday at $42.31.

Latest Ratings for ALKS

DateFirmActionFromTo
Jul 2016JefferiesMaintainsBuy
Jul 2016BarclaysMaintainsOverweight
Jul 2016Cowen & CompanyUpgradesOutperformMarket Perform

View More Analyst Ratings for ALKS
View the Latest Analyst Ratings

Posted-In: David Risinger Morgan StanleyAnalyst Color Reiteration Analyst Ratings

 

Related Articles (ALKS)

View Comments and Join the Discussion!